Donor Milk for Newborns
Trial Summary
What is the purpose of this trial?
The goal of this clinical trial is to learn about the impact of donor milk vs formula supplementation on human milk feeding and the health outcomes of infants who require supplementation in well-baby units. It aims to explore whether supplementation with donor milk vs formula for infants during the initial hospital stay in a well-baby unit will increase both the exclusivity and duration of breastfeeding at 4 months. The Investigators will also explore whether the type of supplementation will positively affect measures of newborns' health, growth, behavior, feeding efficacy, and parental stress. Each participating infant born to a diabetic mother OR born small for his/her gestational age (\<2500 grams) is assigned at random to 2 groups. The groups are: 1) Donor milk: all babies in this group will receive pasteurized donor milk from a trusted milk bank. 2) Formula: all babies in this group will receive formula as a standard of care.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What data supports the effectiveness of the treatment Donor Milk for Newborns?
Research shows that donor human milk can reduce the risk of serious conditions like necrotising enterocolitis (a severe intestinal disease) and late onset sepsis (a blood infection) in low birthweight infants, and it is recommended by the World Health Organization when a mother's milk is unavailable.12345
Is donor milk safe for newborns?
How is donor milk different from other treatments for newborns?
Research Team
Deborah O'Connor, PhD, RD
Principal Investigator
Chair, Department of Nutritional Sciences, University of Toronto
Sharon Unger, MD
Principal Investigator
Sinai Health
Eligibility Criteria
This trial is for newborns born to mothers with any type of diabetes or babies who are small for their gestational age (less than 2500 grams). The infants must be in a well-baby unit and require supplementation. Specific inclusion and exclusion criteria details were not provided.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Infants receive either donor milk or formula supplementation during their initial hospital stay
Follow-up
Participants are monitored for health outcomes and breastfeeding efficacy at 1, 2, 3, and 4 months
Exploratory Assessments
Exploratory outcomes include assessments of infant temperament, parental mental health, and milk cortisol concentrations at 2 and 4 months
Treatment Details
Interventions
- Formula
- Human donor milk
Formula is already approved in European Union, United States, Canada for the following indications:
- Nutritional support for infants
- Nutritional support for infants
- Supplementation for breastfeeding
- Nutritional support for infants
- Supplementation for breastfeeding in well-baby units
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mount Sinai Hospital, Canada
Lead Sponsor
Mitacs
Industry Sponsor